MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
61.35
-0.86
-1.38%
After Hours: 61.35 0 0.00% 16:14 09/24 EDT
OPEN
62.21
PREV CLOSE
62.21
HIGH
62.33
LOW
61.13
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
70.98
52 WEEK LOW
49.26
MARKET CAP
11.88B
P/E (TTM)
165.41
1D
5D
1M
3M
1Y
5Y
1D
Biomarin-Linked ENERGY 2 Trial Termination: What It Means for Rare-Disease Investors
TipRanks · 5h ago
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Seeking Alpha · 8h ago
Tracking John Paulson's Paulson & Company Portfolio: Q2 2026 Update
Seeking Alpha · 1d ago
BioMarin: Why I See Significant Upside Into 2027
Seeking Alpha · 3d ago
Analysts Conflicted on These Healthcare Names: Tilray (TLRY) and BioMarin Pharmaceutical (BMRN)
TipRanks · 3d ago
Weekly Report: what happened at BMRN last week (0914-0918)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)
TipRanks · 6d ago
What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders
Simply Wall St · 09/17 17:24
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.